Details for Patent: 8,071,579
✉ Email this page to a colleague
Which drugs does patent 8,071,579 protect, and when does it expire?
Patent 8,071,579 protects ZEJULA, AKEEGA, LYNPARZA, and RUBRACA, and is included in five NDAs.
This patent has eighty-six patent family members in thirty-eight countries.
Summary for Patent: 8,071,579
| Title: | DNA damage repair inhibitors for the treatment of cancer |
| Abstract: | The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein. |
| Inventor(s): | Ashworth; Alan (London, GB), Jackson; Stephen (Cambridge, GB), Martin; Niall (Cambridge, GB), Smith; Graeme (Cambridge, GB) |
| Assignee: | The Institute of Cancer Research: Royal Cancer Hospital (London, GB) Kudos Pharmaceuticals Limited (Cambridge, GB) |
| Application Number: | 11/001,474 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,071,579
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ZEJULA | niraparib tosylate | CAPSULE;ORAL | 208447-001 | Mar 27, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS | ⤷ Sign Up | ||||
| Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-001 | Aug 11, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION | ⤷ Sign Up | ||||
| Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-002 | Aug 11, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION | ⤷ Sign Up | ||||
| Astrazeneca | LYNPARZA | olaparib | TABLET;ORAL | 208558-001 | Aug 17, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN COMBINATION WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,071,579
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0327844.7 | Dec 1, 2003 |
International Family Members for US Patent 8,071,579
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1633724 | ⤷ Sign Up | C300726 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1633724 | ⤷ Sign Up | CR 2015 00012 | Denmark | ⤷ Sign Up |
| European Patent Office | 1633724 | ⤷ Sign Up | C20150012 00136 | Estonia | ⤷ Sign Up |
| European Patent Office | 1633724 | ⤷ Sign Up | 92680 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
